In the year 2020, the incidence of cases of Calciphylaxis is estimated to be 3,450 to 4,560 in 8 MM countries.
Comprehensive insight on patient segmentation based on age, sex, types (Uremic, and Non-uremic), Clinical Manifestations (induration, plaques, nodules, livedo, or purpura) has been provided into the epidemiology (Incidence, Prevalence, and Mortality) section of the Calciphylaxis and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China. Drug utilization and analysis on the current clinical practice, KOL perspective on upcoming therapies, estimated TPP for pipeline as-sets, clinical characteristics upcoming therapies, and future treatment paradigm.
In terms of pharmacologic therapies, Several drug candidates are in Phase III and II stages of development by various companies. Key assets among these are, sodium thiosulfate; Hope Pharmaceuticals, SNF 472; Sanifit Laboratories, DS1211; Daiichi Sankyo, INZ-701; Inozyme Pharma, INS3001; Inositec. Among these key assets, some of the assets are being designated as an orphan drugs and EMA and US FDA such as Sodium thiosulfate, SNF472. CALISTA is an international study that plans to enroll 111 adult patients with calciphylaxis. Eligible patients will be treated at participating medical centers in Canada and the United States over a three-week period to assess the effect of Sodium Thiosulfate on calciphylaxis-related pain.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,